Ascelia Pharma AB (publ) (ST:ACE) — Stock Price

Skr0.57 SEK
▼ -4.84% today

Ascelia Pharma AB (publ) (ST:ACE) is currently trading at Skr0.57 SEK, down 4.84% today. Over the past 52 weeks, shares have ranged between Skr0.48 and Skr5.10. This page tracks Ascelia Pharma AB (publ)'s live share price on the ST exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Ascelia Pharma AB (publ) market capitalisation.

Ascelia Pharma AB (publ) (ACE) Stock Price Chart — Daily History & Trading Volume

The chart below tracks Ascelia Pharma AB (publ)'s daily closing share price and trading volume on the ST exchange over the past year, giving a clear view of recent price momentum and liquidity.

Ascelia Pharma AB (publ) Income Statement — Revenue, Profit & Earnings by Year

Ascelia Pharma AB (publ)'s annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.

Fiscal Year 20242023202220212020
Total Revenue Skr0.00 Skr0.00 Skr0.00 Skr0.00 Skr0.00
Cost of Revenue Skr938.00K Skr1.05 Million Skr3.89 Million Skr8.72 Million Skr825.00K
Gross Profit Skr-938.00K Skr-1.05 Million Skr-3.89 Million Skr-8.72 Million Skr-825.00K
Research & Development Skr50.80 Million Skr81.27 Million Skr118.11 Million Skr107.57 Million Skr64.76 Million
SG&A Skr18.00 Million Skr19.77 Million Skr14.63 Million Skr8.81 Million Skr18.30 Million
Total Operating Expenses Skr67.19 Million Skr110.91 Million Skr143.78 Million Skr129.17 Million Skr93.26 Million
Operating Income Skr-68.12 Million Skr-110.91 Million Skr-147.01 Million Skr-137.95 Million Skr-93.43 Million
EBITDA Skr-67.69 Million Skr-108.56 Million Skr-132.06 Million Skr-128.42 Million Skr-98.91 Million
EBIT Skr-67.77 Million Skr-109.61 Million Skr-133.11 Million Skr-129.45 Million Skr-99.73 Million
Interest Expense Skr7.54 Million Skr14.00K Skr48.00K Skr77.00K Skr13.00K
Income Before Tax Skr-80.12 Million Skr-109.61 Million Skr-133.16 Million Skr-129.52 Million Skr-99.75 Million
Income Tax Expense Skr-95.00K Skr-319.00K Skr-1.93 Million Skr-3.62 Million Skr-1.05 Million
Net Income Skr-80.03 Million Skr-109.29 Million Skr-131.22 Million Skr-125.90 Million Skr-98.70 Million

Ascelia Pharma AB (publ) Balance Sheet — Assets, Liabilities & Shareholder Equity

The balance sheet below summarizes Ascelia Pharma AB (publ)'s financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.

Fiscal Year 20242023202220212020
Total Assets Skr140.92 Million Skr87.07 Million Skr218.57 Million Skr333.49 Million Skr255.37 Million
Total Current Assets Skr83.72 Million Skr28.94 Million Skr160.87 Million Skr274.61 Million Skr196.32 Million
Cash & Equivalents — — — — —
Short-term Investments — Skr1.00K — — Skr0.00
Net Receivables Skr5.68 Million Skr580.00K Skr4.53 Million Skr5.56 Million Skr2.83 Million
Inventory Skr-6.08 Million — Skr6.79 Million — Skr8.28 Million
Property, Plant & Equipment Skr124.00K Skr1.06 Million Skr625.00K Skr1.82 Million Skr1.99 Million
Goodwill — — — — —
Total Liabilities Skr61.98 Million Skr12.74 Million Skr37.71 Million Skr25.66 Million Skr19.32 Million
Total Current Liabilities Skr61.98 Million Skr12.57 Million Skr37.52 Million Skr25.11 Million Skr18.36 Million
Long-term Debt Skr0.00 — — — —
Net Debt Skr-49.86 Million Skr-20.80 Million Skr-149.07 Million Skr-259.94 Million Skr-182.91 Million
Total Stockholder Equity Skr78.94 Million Skr74.33 Million Skr180.86 Million Skr307.83 Million Skr236.06 Million
Retained Earnings Skr-740.97 Million Skr-639.96 Million Skr-533.48 Million Skr-405.83 Million Skr-286.37 Million

Ascelia Pharma AB (publ) Cash Flow Statement — Operating, Investing & Financing Activities

This cash flow statement breaks down how Ascelia Pharma AB (publ) generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.

Fiscal Year 20242023202220212020
Operating Cash Flow Skr-62.84 Million Skr-126.79 Million Skr-125.26 Million Skr-116.56 Million Skr-85.53 Million
Capital Expenditures Skr0.00 Skr126.79 Million Skr65.00K Skr38.00K Skr397.00K
Free Cash Flow Skr-62.84 Million Skr-126.79 Million Skr-125.33 Million Skr-116.60 Million Skr-85.92 Million
Investing Cash Flow Skr0.00 Skr46.00K Skr-65.00K Skr-38.00K Skr75.99 Million
Financing Cash Flow Skr115.19 Million Skr-936.00K Skr-1.10K Skr184.87 Million Skr92.72 Million
Dividends Paid — — — — —
Stock-Based Compensation Skr4.34 Million Skr2.93 Million Skr1.63 Million Skr5.92 Million Skr7.87 Million
Depreciation — Skr1.05 Million Skr1.05 Million Skr1.03 Million Skr825.00K
Change in Cash Skr53.40 Million Skr-127.70 Million Skr-112.04 Million Skr76.91 Million Skr76.17 Million

Ascelia Pharma AB (publ) Earnings History — EPS Actual vs. Analyst Estimates

Track Ascelia Pharma AB (publ)'s quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.

Report Date EPS Actual EPS Estimate Surprise
Nov 05, 2025 -0.13 -0.10 -30.00%
Aug 21, 2025 -0.20 -0.10 -100.00%
May 16, 2025 -0.23 -0.20 -15.00%
Feb 07, 2025 -0.29 -0.20 -45.00%
Nov 07, 2024 -0.42 -0.20 -110.00%
Aug 15, 2024 -0.39 -0.40 +2.50%
May 16, 2024 -0.50 -0.40 -25.00%
Feb 09, 2024 -0.31 -0.40 +22.50%